NEWS
- Mar. 4, 2025
- Meiji Seika Pharma Invests in Osivax SAS
- Jan. 27, 2025
- Japanese Government Delivers KM Biologics' Mpox Vaccine to the Democratic Republic of the Congo
- Nov. 20, 2024
- KM Biologics Receives WHO Emergency Use Listing for its Mpox Vaccine
- Sep. 10, 2024
- Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan
- Jul. 10, 2024
- KM Biologics is Selected Through an Open Call for Conducting the ”Large-scale Vaccine Clinical Study Project“ by the Ministry of Health, Labour and Welfare
- Apr. 22, 2024
- Our disease awareness campaign for World Hemophilia Day
- Apr. 21, 2023
- Our disease awareness campaign for World Hemophilia Day
- Mar. 25, 2021
- KM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)
- Dec. 21, 2018
- Nature, November special issue — KM Biologics: Safeguarding public health
- Oct. 31, 2018
- KM Biologics launches new website
